Global Immunology Drug Report Thumbnail

Global Immunology Drug Market by Type (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication), By Application (Hospitals, Clinics, Cancer Research Centers and Institutes) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

  • Report ID: PH-689
  • Author: Up Market Research
  • Rating: 4.5
  • Total Reviews: 61
  • No. Of Pages: 226
  • Format:
  • Pub. Date: 2021-03-01
  • Share:

The Global Immunology Drugs Market size is expected to grow from USD 4.4 billion in 2021, to reach USD 6.6 billion by 2028, at a CAGR of 5.7% during the forecast period (2021 - 2028). The growth in this market can be attributed to the increased prevalence of autoimmune diseases and cancer, as well as advancements in treatment methods for patients with these conditions.


Immunology Drugs are a group of medicines that work to treat or control the body's immune system. These treatments can be administered as either intravenous medications, oral tablets, injections, or topical creams (e.g., ointments). Immunology drugs have a range of uses including treating autoimmune diseases and cancer cells in order to help manage symptoms related to these conditions.


On the basis of Types, the market is segmented into Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine Therapies, Immunosuppressive Medication.


Monoclonal Antibodies (mAb):

Monoclonal Antibodies are a type of antibody that is produced by the immune system in response to an antigen. They mainly work as part of what’s called “the adaptive immune response,” which includes cells like B and T lymphocytes, macrophages, natural killer cells, and dendritic cells. These antibodies attach themselves to antigens for identification purposes before triggering other parts of the body's immune system to attack those antigens. The human body produces monoclonal antibodies naturally - they're not made synthetically or from animal sources (such as rabbits).


Antibody Drug Conjugates:

Antibody-Drug Conjugates is a type of antibody-based drug that includes one or more drugs covalently attached to the protein carrier. It induces antibodies to bind with cancer cells, which leads to their destruction both in vitro and in vivo as they are internalized by tumor cells and released from them through lysosomal mechanisms.


Interferon and Cytokine Therapies:

Interferon and Cytokine therapies are broadly divided into two categories: biological agents (interferons) and chemical agents (cytokines). Biological agents, such as subcutaneous photopheresis, T-cell therapy, or peritoneal dialysis with an immunosuppressant agent for kidney transplantation, have been in use to treat autoimmune diseases.

On the other hand, cytokines are used mainly in cancer treatment. They can be administered directly to a tumor site by injection or intravenously; alternatively, they may act indirectly on nearby cells by increasing their sensitivity to radiation therapy. Examples of these include GM-CSF which is used for many types of cancers including multiple myeloma and leukemia.


Immunosuppressive Medication:

The word "immunosuppressive" refers to a medication that suppresses the immune system. The aim of these drugs is usually to inhibit or prevent an overreaction of the body's immune response, such as in autoimmune disorders and transplant rejection. Immunosuppressive drugs are also used for chemotherapy patients who have undergone bone marrow transplants.


On the basis of Application, the market is segmented into Hospitals, Clinics, and Cancer Research Centers & Institutes. Hospitals are expected to have a higher market share than clinics for the forecast period. The main reason can be attributed to hospitals being more equipped with advanced equipment needed for treatment procedures which are not available in most clinics. 

Hospitals are the most active players in this industry. The growing demand for Immunology Drugs is a reflection of their increasing use among hospital patients to treat cancer, immunodeficiency disorders, and autoimmune diseases. Moreover, hospitals also provide chemotherapy sessions using these drugs to reduce toxic side effects on the body tissues and blood cells that may be caused by chemotherapy drugs which can become fatal if not dealt with timely enough.


On the basis of Region, the market is segmented ed into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for nearly one-third of the global cancer research centers and institutes segment due to greater awareness about various skin cancers among patients as well as its high incidence rate. The major reason behind this can be attributed to the increasing incidence rates of various skin cancers among patients coupled with greater awareness about it by people living in the US & Canada. Latin America has been witnessing steady growth over recent years and is expected to be the fastest-growing region for immunology drugs in the coming years.


Up Market Research published a new report titled “Immunology Drug Market research report which is segmented by Types (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication), By Applications (Hospitals, Clinics, Cancer Research Centers and Institutes), By Players/Companies Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune Inc., Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Bayer AG, Sanofi Aventis LLC.”. 


Report Scope

Report Attributes Report Details
Report Title Immunology Drug Market Research Report
By Type Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication
By Application Hospitals, Clinics, Cancer Research Centers and Institutes
By Companies Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune Inc., Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Bayer AG, Sanofi Aventis LLC.
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2020
Historical Year 2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year 2028
Number of Pages 226
Number of Tables & Figures 159
Customization Available Yes, the report can be customized as per your need.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Immunology Drug Industry Outlook

Global Immunology Drug Market Report Segments:

The market is segmented by Type Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication and By Application Hospitals, Clinics, Cancer Research Centers and Institutes.


Some of the companies that are profiled in this report are:

  1. Abbott Laboratories
  2. Active Biotech
  3. Eli Lilly and Company
  4. Autoimmune Inc.
  5. Pfizer
  6. GlaxoSmithKline plc
  7. Seattle Genetics
  8. Genentech
  9. F. Hoffmann-La Roche Ltd.
  10. Eisai Co.
  11. Bayer AG
  12. Sanofi Aventis LLC.

Immunology Drug Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.


Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Immunology Drug Market

Overview of the regional outlook of the Immunology Drug Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Immunology Drug Market Overview

Highlights of The Immunology Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Immunology Drug Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

                1. Monoclonal Antibodies (mAb)

                2. Antibody Drug Conjugates

                3. Interferon and Cytokine therapies

                4. Immunosuppressive medication

       7. By Application:

                1. Hospitals

                2. Clinics

                3. Cancer Research Centers and Institutes

  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Immunology Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.


How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Immunology Drug Market Statistics

Reasons to Purchase the Immunology Drug Market Report:

  • The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
  • Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
  • Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
  • The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
  • Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunology Drug Market Overview
   4.1 Introduction 
      4.1.1 Market Taxonomy 
      4.1.2 Market Definition 
      4.1.3 Macro-Economic Factors Impacting the Market Growth 
   4.2 Immunology Drug Market Dynamics 
      4.2.1 Market Drivers 
      4.2.2 Market Restraints 
      4.2.3 Market Opportunity 
   4.3 Immunology Drug Market - Supply Chain Analysis 
      4.3.1 List of Key Suppliers 
      4.3.2 List of Key Distributors 
      4.3.3 List of Key Consumers 
   4.4 Key Forces Shaping the Immunology Drug Market 
      4.4.1 Bargaining Power of Suppliers 
      4.4.2 Bargaining Power of Buyers 
      4.4.3 Threat of Substitution 
      4.4.4 Threat of New Entrants 
      4.4.5 Competitive Rivalry 
   4.5 Global Immunology Drug Market Size & Forecast, 2018-2028 
      4.5.1 Immunology Drug Market Size and Y-o-Y Growth 
      4.5.2 Immunology Drug Market Absolute $ Opportunity 

Chapter 5 Global Immunology Drug Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Immunology Drug Market Size Forecast by Type
      5.2.1 Monoclonal Antibodies (mAb)
      5.2.2 Antibody Drug Conjugates
      5.2.3 Interferon and Cytokine therapies
      5.2.4 Immunosuppressive medication
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Immunology Drug Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Immunology Drug Market Size Forecast by Applications
      6.2.1 Hospitals
      6.2.2 Clinics
      6.2.3 Cancer Research Centers and Institutes
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Immunology Drug Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Immunology Drug Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Immunology Drug Analysis and Forecast
   9.1 Introduction
   9.2 North America Immunology Drug Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Immunology Drug Market Size Forecast by Type
      9.6.1 Monoclonal Antibodies (mAb)
      9.6.2 Antibody Drug Conjugates
      9.6.3 Interferon and Cytokine therapies
      9.6.4 Immunosuppressive medication
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Immunology Drug Market Size Forecast by Applications
      9.10.1 Hospitals
      9.10.2 Clinics
      9.10.3 Cancer Research Centers and Institutes
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Immunology Drug Analysis and Forecast
   10.1 Introduction
   10.2 Europe Immunology Drug Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Immunology Drug Market Size Forecast by Type
      10.6.1 Monoclonal Antibodies (mAb)
      10.6.2 Antibody Drug Conjugates
      10.6.3 Interferon and Cytokine therapies
      10.6.4 Immunosuppressive medication
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Immunology Drug Market Size Forecast by Applications
      10.10.1 Hospitals
      10.10.2 Clinics
      10.10.3 Cancer Research Centers and Institutes
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Immunology Drug Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Immunology Drug Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Immunology Drug Market Size Forecast by Type
      11.6.1 Monoclonal Antibodies (mAb)
      11.6.2 Antibody Drug Conjugates
      11.6.3 Interferon and Cytokine therapies
      11.6.4 Immunosuppressive medication
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Immunology Drug Market Size Forecast by Applications
      11.10.1 Hospitals
      11.10.2 Clinics
      11.10.3 Cancer Research Centers and Institutes
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Immunology Drug Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Immunology Drug Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Immunology Drug Market Size Forecast by Type
      12.6.1 Monoclonal Antibodies (mAb)
      12.6.2 Antibody Drug Conjugates
      12.6.3 Interferon and Cytokine therapies
      12.6.4 Immunosuppressive medication
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Immunology Drug Market Size Forecast by Applications
      12.10.1 Hospitals
      12.10.2 Clinics
      12.10.3 Cancer Research Centers and Institutes
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Immunology Drug Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Immunology Drug Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Immunology Drug Market Size Forecast by Type
      13.6.1 Monoclonal Antibodies (mAb)
      13.6.2 Antibody Drug Conjugates
      13.6.3 Interferon and Cytokine therapies
      13.6.4 Immunosuppressive medication
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Immunology Drug Market Size Forecast by Applications
      13.10.1 Hospitals
      13.10.2 Clinics
      13.10.3 Cancer Research Centers and Institutes
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Immunology Drug Market: Competitive Dashboard
   14.2 Global Immunology Drug Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Abbott Laboratories
      14.3.2 Active Biotech
      14.3.3 Eli Lilly and Company
      14.3.4 Autoimmune Inc.
      14.3.5 Pfizer
      14.3.6 GlaxoSmithKline plc
      14.3.7 Seattle Genetics
      14.3.8 Genentech
      14.3.9 F. Hoffmann-La Roche Ltd.
      14.3.10 Eisai Co.
      14.3.11 Bayer AG
      14.3.12 Sanofi Aventis LLC.
Segments Covered in the Report
The global Immunology Drug market has been segmented based on

By Types
  • Monoclonal Antibodies (mAb)
  • Antibody Drug Conjugates
  • Interferon and Cytokine therapies
  • Immunosuppressive medication
By Applications
  • Hospitals
  • Clinics
  • Cancer Research Centers and Institutes
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Abbott Laboratories
  • Active Biotech
  • Eli Lilly and Company
  • Autoimmune Inc.
  • Pfizer
  • GlaxoSmithKline plc
  • Seattle Genetics
  • Genentech
  • F. Hoffmann-La Roche Ltd.
  • Eisai Co.
  • Bayer AG
  • Sanofi Aventis LLC.

Buy Report